A recent article in Analytical Chemistry, found here, describes the use of liquid extraction surface analysis mass spectrometry (LESA-MS), to study drug distribution in tissue. While this method is effective at exploring surface distribution, frozen aliquotting enables the precise capture of larger-depth frozen tissue aliquots from specific tissue sections, enabling detailed drug distribution and excretion studies. To learn more about frozen aliquotting, visit http://www.cryoxtract.com/applications/bioanalysis
A July, 2015 publication of a study in Scientific Reports found here investigates the interactions between gut microbiota and berberine, a dietary supplement used for the treatment of lipid- and glucose-related disorders. In the study, researchers found that gut microbiota reduced berberine to an absorbable form in the intestine, increasing its effectiveness. The authors conclude that there can be critical interaction between intestinal bacteria and orally-administered drugs and suggest that the effect of gut microbiota on orally-administered drug metabolism should be investigated during drug development.
Failures in incurred sample reanalysis (ISR) can be very problematic to life science researchers working in drug discovery and regulated bioanalysis. As a tool for confirming reliability of bioanalytical measurements, concerns with and failures of ISR can significantly delay drug development and can be very costly to remedy. An article in AAPS earlier this year (found here) discusses difficulties with ISR imprecision particularly in small molecule studies.
Integrating data from tissue imaging, genomic databases, and clinical results could be a major key in the journey toward truly personalized medicine, according to a recent article in Genetic Engineering and Biotechnology News (found here). Careful maintenance of patient data correlated with tissue samples is one element of the best practices necessary for a truly integrated data approach to drug discovery and development.
Biopreservation and Biobanking published an article in their June edition that offers an alternative for data analysis and disclosure for biobanks. Outlined here, authors Kuiper, van den Heuvel and Swertz argue for a data analysis model that addresses privacy control issues while allowing for greater access to usable information for the support of valuable research efforts using their Statistical Disclosure Control model. This approach steps outside the more traditional methods of suppression and obfuscation.
The President’s Precision Medicine Initiative, introduced here in the New England Journal of Medicine, is an opportunity to bring researchers and professionals together to promote expanding efforts in cancer genomics in the near term, and create a national network of scientists dedicated to implementing precision medicine on a larger, nationwide scale.
Research results in cancer genomics depend upon the quality of information that can be obtained from biological samples and the ability to expand the information that can be extracted from these samples. The importance of improved and standardized sample handling and processing methodologies in order to achieve the high resolution data necessary for true personalized medicine cannot be over-emphasized. CryoXtract aims to be a leader in this effort with its frozen alliquotting technology, enabling researchers to maintain biospecimen integrity and utilize these highly valuable samples efficiently and productively.
Topics: Press Summaries
Fortune magazine recently highlighted the work of Danone yogurt manufacturer at their laboratory in Utrecht, Netherlands where scientists explore the effects of food products on the human digestive system using a model gastrointestinal tract. The TNO Intestinal Model ("TIM") allows researchers to explore the possibility of healing damage to the gut microbiome with an appropriately engineered diet. The results of work with TIM to explore the effects of pre and probiotics, for example, could have dramatic impact on the exploding superfoods marketplace.
The National Comprehensive Cancer Network hosted its policy summit on June 8, 2015 in Washington, D.C. Discussions centering around the theme “Emerging Issues in Tissue Allocation” addressed increasing concern in the oncology research community about the proper acquisition and management of highly valuable, and often especially fragile, biospecimen resources.
A review published in FEMS Microbiology Reviews in May summarizes research into the microbiome of blood in non-communicable diseases. The overview emphasizes the microbial component of chronic, inflammatory diseases that have been difficult to investigate due to non-culturability of dormant pathogens. As culturing methods improve, however, more information on the authentic blood microbiome is coming to light.